Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[Lu-177]-PNT2002 in metastatic castration-resistant prostate cancer
NCT04647526Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2021
- Primary completion
- Nov 2023
- Modality
- Peptides
- Countries
- 6
01
Overview
Phase 3, randomised, open-label trial of Lu-PNT2002 in metastatic castration-resistant prostate cancer (mCRPC) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Radiographic Progression-Free Survival at 23 months. Started Feb 2021; status: active, not recruiting.
02
Drugs
Lu-PNT2002
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04647526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04647526.